Cullinan Therapeutics Inc. (CGEM) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CGEM currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($17.91) and Max Pain ($16.22) forces dealer call-delta covering toward $24.35.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Cullinan Therapeutics Inc. (CGEM) slipped -0.71% to $15.45, trading at 53% of its 52-week range ($6.73 – $23.19). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Cullinan Therapeutics (CGEM) is back in focus after regulators in the U.S. and Australia cleared a global Phase 1b/2a trial of velinotamig in difficult immune thrombocytopenia and warm autoimmune hemolytic anemia. Cullin
Cullinan Therapeutics has more than doubled over the past year, which puts a sharp spotlight on whether that move still lines up with the strength of its balance sheet and book value. After a series of clinical updates,
The mean of analysts' price targets for Cullinan Therapeutics (CGEM) points to a 129.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in r
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $40 to $41.
Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHA Study expands immunology portfolio into autoimmune cytopenias, evaluating a short
Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHAStudy expands immunology portfolio into autoimmune cytopenias, evaluating a
BTIG analyst Julian Harrison reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $40 price target.
PRINCETON, N.J. & CAMBRIDGE, Mass., October 19, 2026--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib mono
Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (NASDAQ:CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CGEM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CGEM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Cullinan Therapeutics Inc. (CGEM) ranks #775 by composite RQD confidence (36/100, grade D-) and #362 by equity capitalization ($994.3M). Within this direct 5-issuer industry benchmark cohort, CGEM leads on earnings valuation at N/A trailing P/E, while CGEM leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with CGEM at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CGEM
ACTIVE
Cullinan Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -0.71% | $994.3M | Benchmark Subject |
| ODTX Odyssey Therapeutics Inc. | C- | 59/100 | — | — | — | +1.48% | $953.0M | /odtx-vs-cgem → |
| PRME Prime Medicine Inc. | E | 21/100 | — | — | -35.0% | -2.24% | $950.4M | /prme-vs-cgem → |
| MGTX MeiraGTx Holdings plc | E | 27/100 | — | — | -35.0% | -0.46% | $932.1M | /mgtx-vs-cgem → |
| GLUE Monte Rosa Therapeutics Inc. | E | 33/100 | — | — | -35.0% | +0.18% | $927.4M | /glue-vs-cgem → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cullinan Therapeutics Inc. (CGEM) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$219.9M, operating cash flow of -$175.8M, and free cash flow of -$175.8M (-21.0% YoY). On the balance sheet, CGEM closed FY2025 with $448.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$219.9M | -$175.8M | -$175.8M | $448.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$167.6M | -$145.3M | -$145.3M | $621.8M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$155.1M | -$134.3M | -$134.3M | — | — |
As of 2026-11-01, Cullinan Therapeutics Inc. (NASDAQ: CGEM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $15.45 (-0.71% 1D, market cap $994.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CGEM ranks #775 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CGEM carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ODTX (Odyssey Therapeutics Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $953.0M) and PRME (Prime Medicine Inc.) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M). Among the 5-stock peer group, CGEM leads on earnings multiple (N/A) while CGEM leads on capital efficiency (-35.0% ROIC).
Per CGEM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001789972), Cullinan Therapeutics Inc. generated $0 in revenue, -$219.9M in net income, and -$175.8M in free cash flow against $448.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CGEM last traded at $15.45 (-0.71% on volume of 460,099 shares), positioning the stock -13.74% below its 50-day simple moving average ($17.91) and -2.28% below its 200-day simple moving average ($15.81). Across its 52-week range of $6.73 to $23.19, CGEM sits at the 53.0% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.52 to $17.38).
Why CGEM Stock slipped -0.71% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.